Lyhyt kuvaus
The Norwegian Institute of Public Health shall enter into a contract for the purchase of a combination vaccine for diphtheria, tetanus, whooping cough, polio, Hib and hepatitis B (hexavalent vaccine), for the national vaccine programme. The tender contest is carried out on behalf of the Norwegian Institute of Public Health (HOD). Norway has had a hexavalent vaccine programme since 2016. The current contract expires 31.12.2019 and shall be replaced by a new contract subsequent to the tender competition.
The procurement shall be implemented as an open tender contest in accordance with the Public Procurement Regulations' Parts 1 and 3. The procurement shall be implemented electronically via the CTM-KGV portal (Eu-Supply) and the tender notice is published in Doffin and TED.